0.5771
price down icon6.50%   -0.0401
after-market Dopo l'orario di chiusura: .61 0.0329 +5.70%
loading
Precedente Chiudi:
$0.6172
Aprire:
$0.6172
Volume 24 ore:
1.04M
Relative Volume:
6.36
Capitalizzazione di mercato:
$51.77M
Reddito:
-
Utile/perdita netta:
$-30.15M
Rapporto P/E:
-0.6342
EPS:
-0.91
Flusso di cassa netto:
$-31.63M
1 W Prestazione:
-16.71%
1M Prestazione:
-34.46%
6M Prestazione:
-62.03%
1 anno Prestazione:
-71.14%
Intervallo 1D:
Value
$0.49
$0.6642
Intervallo di 1 settimana:
Value
$0.49
$0.71
Portata 52W:
Value
$0.49
$2.75

Context Therapeutics Inc Stock (CNTX) Company Profile

Name
Nome
Context Therapeutics Inc
Name
Telefono
267-225-7416
Name
Indirizzo
2001 MARKET STREET, PHILADELPHIA
Name
Dipendente
9
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-19
Name
Ultimi documenti SEC
Name
CNTX's Discussions on Twitter

Confronta CNTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
CNTX
Context Therapeutics Inc
0.5771 62.16M 0 -30.15M -31.63M -0.91
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-21 Iniziato William Blair Outperform
2025-01-08 Iniziato JMP Securities Mkt Outperform
2024-11-25 Iniziato D. Boral Capital Buy
2024-05-16 Iniziato Piper Sandler Overweight

Context Therapeutics Inc Borsa (CNTX) Ultime notizie

pulisher
May 29, 2025

Context Therapeutics Names Dr. Karen Chagin as Chief Medical Officer - MyChesCo

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CN - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics (CNTX) Names New Chief Medical Officer | CNTX Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics names new CMO to advance T cell therapies - Investing.com

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Context Therapeutics Appoints Developer of First FDA-Approved Solid Tumor Cell Therapy as Chief Medical Officer - Stock Titan

May 29, 2025
pulisher
May 18, 2025

Context Therapeutics Grants Stock Options to New Hires as Part of Strategic Talent Growth - MSN

May 18, 2025
pulisher
May 17, 2025

Context Therapeutics Names Dr. Karen Smith as Interim Chief Medical Officer - MSN

May 17, 2025
pulisher
May 16, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $5.40 Consensus Price Target from Analysts - Defense World

May 16, 2025
pulisher
May 15, 2025

Context Therapeutics Reports Q1 2025 Financial Results and Clinical Progress - MSN

May 15, 2025
pulisher
May 12, 2025

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 12, 2025
pulisher
May 12, 2025

William Blair Has Positive Outlook of CNTX FY2025 Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

Research Analysts Offer Predictions for CNTX Q2 Earnings - Defense World

May 12, 2025
pulisher
May 10, 2025

D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

May 10, 2025
pulisher
May 09, 2025

UTR Therapeutics files IND application for UTRxM1-18 for c-MYC-driven cancers - BioWorld MedTech

May 09, 2025
pulisher
May 08, 2025

Context Therapeutics Showcases Promising CT-95 Data at AACR Annual Meeting - MSN

May 08, 2025
pulisher
May 08, 2025

Context Therapeutics (CNTX) Receives Continued 'Buy' Rating from Analyst | CNTX Stock News - GuruFocus

May 08, 2025
pulisher
May 07, 2025

FORE Biotherapeutics’ Plixorafenib Study to Be Highlighted at ASCO 2025 - MyChesCo

May 07, 2025
pulisher
May 07, 2025

CONTEXT THERAPEUTICS Earnings Results: $CNTX Reports Quarterly Earnings - Nasdaq

May 07, 2025
pulisher
May 07, 2025

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results - GlobeNewswire

May 07, 2025
pulisher
May 06, 2025

Marshall Wace LLP Buys New Stake in Context Therapeutics Inc. (NASDAQ:CNTX) - The AM Reporter

May 06, 2025
pulisher
May 05, 2025

Context Therapeutics Appoints Karen Smith as Interim CMO - citybiz

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics (CNTX) Names Karen Smith as Interim Chief Medical Officer | CNTX Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO - Investing.com

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics appoints new interim CMO By Investing.com - Investing.com South Africa

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Announces Chief Medical Officer Transition - GlobeNewswire

May 05, 2025
pulisher
May 05, 2025

Context Therapeutics Inc Announces Executive Changes Effective May 10, 2025 - marketscreener.com

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Boosts Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - Defense World

May 05, 2025
pulisher
May 02, 2025

What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World

May 02, 2025
pulisher
May 02, 2025

Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World

May 02, 2025
pulisher
May 01, 2025

Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World

May 01, 2025
pulisher
Apr 30, 2025

Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics reports progress in cancer treatment - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics Inc. Announces Preclinical Data Supporting Unique Binding Mechanism of CT-95 and Progress in Phase 1 Clinical Trial - Nasdaq

Apr 30, 2025
pulisher
Apr 30, 2025

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan

Apr 30, 2025
pulisher
Apr 24, 2025

Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World

Apr 24, 2025
pulisher
Apr 22, 2025

Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq

Apr 21, 2025
pulisher
Apr 21, 2025

Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts

Apr 21, 2025
pulisher
Apr 21, 2025

William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada

Apr 21, 2025

Context Therapeutics Inc Azioni (CNTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):